Association of heart rate with heart failure outcomes and the effects of empagliflozin in patients with preserved ejection fraction - EMPEROR-Preserved trial

被引：0
|
作者：
Boehm, M. [1 ]
Anker, S. D. [2 ]
Mahfoud, F. [1 ]
Filippatos, G. [3 ]
Ferreira, J. P. [4 ]
Pocock, S. J. [5 ]
Brueckmann, M. [6 ]
Linetzky, B. [7 ]
Schueler, E. [8 ]
Wanner, C. [9 ]
Zannad, F. [4 ]
Packer, M. [10 ]
Butler, J. [11 ]
机构：
[1] Univ Hosp Saarland, Clin Internal Med Cardiol Angiol & Intens Care Me, Homburg, Germany
[2] Charite Univ Med Berlin, Dept Cardiol CVK, Berlin, Germany
[3] Natl & Kapodistrian Univ Athens, Athens Univ Hosp, Sch Med, Athens, Greece
[4] Univ Lorraine, Nancy, France
[5] London Sch Hyg & Trop Med, London, England
[6] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
[7] Eli Lilly Interamer Inc, Buenos Aires, DF, Argentina
[8] mainanalyt GmbH, Sulzbach, Germany
[9] Wuerzburg Univ Clin, Wurzburg, Germany
[10] Baylor Univ Med Ctr, Dallas, TX USA
[11] Baylor Scott & White Hlth, Dallas, TX USA
来源：
EUROPEAN HEART JOURNAL | 2022年 / 43卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：983 / 983
页数：1
相关论文
共 50 条
  • [1] EMPEROR-Preserved: Empagliflozin and Outcomes in Heart Failure with a Preserved Ejection Fraction and CKD
    Zannad, Faiez
    Kraus, Bettina J.
    Zeller, Cordula
    Pocock, Stuart
    Packer, Milton
    Filippatos, Gerasimos
    Ferreira, Joao Pedro
    Anker, Stefan D.
    Butler, Javed
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : B3 - B3
  • [2] Anaemia, erythrocytosis, and empagliflozin in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial
    Ferreira, Joao Pedro
    Zannad, Faiez
    Vasques-Novoa, Francisco
    Neves, Joao Sergio
    Filippatos, Gerasimos
    Pocock, Stuart J.
    Butler, Javed
    Packer, Milton
    Anker, Stefan D.
    EUROPEAN HEART JOURNAL, 2024,
  • [3] Liver tests, cardiovascular outcomes and effects of empagliflozin in patients with heart failure and preserved ejection fraction: The EMPEROR-Preserved trial
    Boehm, Michael
    Butler, Javed
    Krawczyk, Marcin
    Mahfoud, Felix
    Haring, Bernhard
    Filippatos, Gerasimos
    Ferreira, Joao Pedro J.
    Pocock, Stuart
    Brueckmann, Martina
    Ofstad, Anne Pernille
    Schueler, Elke
    Wanner, Christoph
    Verma, Subodh
    Packer, Milton D.
    Anker, Stefan
    EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 (08) : 1375 - 1383
  • [4] Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction: the EMPEROR-Preserved trial
    Boehm, Michael
    Butler, Javed
    Coats, Andrew
    Lauder, Lucas
    Mahfoud, Felix
    Filippatos, Gerasimos
    Ferreira, Joao Pedro
    Pocock, Stuart J.
    Brueckmann, Martina
    Hauske, Sibylle J.
    Schueler, Elke
    Wanner, Christoph
    Verma, Subodh
    Zannad, Faiez
    Packer, Milton
    Anker, Stefan D.
    EMPEROR Preserved Trial Committees Investigators
    EUROPEAN HEART JOURNAL, 2025, 46 (14) : 1304 - 1317
  • [5] Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction EMPEROR-Preserved Trial
    Packer, Milton
    Butler, Javed
    Zannad, Faiez
    Filippatos, Gerasimos
    Ferreira, Joao Pedro
    Pocock, Stuart J.
    Carson, Peter
    Anand, Inder
    Doehner, Wolfram
    Haass, Markus
    Komajda, Michel
    Miller, Alan
    Pehrson, Steen
    Teerlink, John R.
    Schnaidt, Sven
    Zeller, Cordula
    Schnee, Janet M.
    Anker, Stefan D.
    CIRCULATION, 2021, 144 (16) : 1284 - 1294
  • [6] Heart failure outcomes according to heart rate and effects of empagliflozin in patients of the EMPEROR-Preserved trial
    Boehm, Michael
    Butler, Javed
    Mahfoud, Felix
    Filippatos, Gerasimos
    Ferreira, Joao Pedro
    Pocock, Stuart J.
    Slawik, Jonathan
    Brueckmann, Martina
    Linetzky, Bruno
    Schueler, Elke
    Wanner, Christoph
    Zannad, Faiez
    Packer, Milton
    Anker, Stefan D.
    EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 (10) : 1883 - 1891
  • [7] EMPEROR-Preserved: Empagliflozin and Outcomes in Heart Failure with a Preserved Ejection Fraction and Chronic Kidney Disease
    Wanner, Christoph
    INTERNIST, 2022, 63 (SUPPL 3): : 349 - 349
  • [8] Uric Acid and Treatment With Empagliflozin in Heart Failure With Preserved Ejection Fraction: The EMPEROR-Preserved Trial
    Doehner, Wolfram
    CIRCULATION, 2022, 146
  • [9] Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial
    Boehm, Michael
    Anker, Stefan
    Mahfoud, Felix
    Lauder, Lucas
    Filippatos, Gerasimos
    Ferreira, Joao Pedro
    Pocock, Stuart J.
    Brueckmann, Martina
    Saloustros, Ilias
    Schueler, Elke
    Wanner, Christoph
    Zannad, Faiez
    Packer, Milton
    Butler, Javed
    EUROPEAN HEART JOURNAL, 2023, 44 (05) : 396 - 407
  • [10] EFFECTS OF EMPAGLIFLOZIN IN FEMALE AND MALE PATIENTS WITH HEART FAILURE AND PRESERVED EJECTION FRACTION: RESULTS FROM THE EMPEROR-PRESERVED TRIAL
    Butler, Javed
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 79 (09) : 311 - 311
12345